Novo Nordisk successfully completes phase 1b/2a trial with …
2 days ago · Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...
Novo Nordisk shares pop on early-stage weight loss drug trial …
2 days ago · The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Shares Soar as Experimental Shot Shows 22% Weight Loss
2 days ago · Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.
Novo Nordisk shares jump on fresh trial results - Financial Times
2 days ago · Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per cent on Friday after the pharmaceutical group announced positive results from the latest trial of weight-loss ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Latest news - Novo Nordisk
Jan 8, 2025 · Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Company announcements & press releases - Novo Nordisk
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
News Details - novonordisk.com
Sep 20, 2024 · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
News details - Novo Nordisk
Mar 8, 2024 · Novo Nordisk's commitment to the obesity and cardiovascular community is a long-term one, and we are investing significantly to build capacity to meet increasing demand. Please visit WegovySupply.com for the latest information.
Novo Nordisk U.S. News & Media Hub | Novo Nordisk U.S.
View financial meetings and events, strategic aspirations for 2025 and contact information for investor relations. A place to find different points of view from inside Novo Nordisk and the communities we serve. Welcome to Novo Nordisk's U.S. news and media hub.